EPCAM and cancer: Consequently, EpCAM-positive cancer cells are highly efficiently killed by catumaxomab, which induces a concerted attack of T cells and accessory immune cells like monocytes, dendritic cells and NK-cells and thereby even elicits a vaccination effect [11, 12].